SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 695.46+2.0%Nov 13 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Miljenko Zuanic9/6/2019 2:38:53 PM
  Read Replies (1) of 3557
 
The next real test for REGN and its PD1 drug, cemiplimab, are Pemb data release at ESMO this month, as LBA (KEYNOTE-629).

Also, Merck is now running Pemb as adjuvant for resected/radiated aCSCC (KEYNOTE-630),
clinicaltrials.gov
...so comparing cem P2 to pemb P2 cscc appears as fist idea does REGN have real chances in IO???
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News